2024

Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45(5):406-418. PMID: 38614815.

2023

Loos P, Short L, Savage G, Evgin L. Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy. Methods Mol Biol. 2024;2748:41-53.

​

Alvarez-Breckenridge C, Anderson KG, Correia AL,  Demehri S, Dinh HQ, Dixon KO, Dunn GP, Evgin L, Goc J, Good Z, Hacohen N, Han P, Hanč P, Hickey J, Kersten K, Liu BC, Buque A, Miao Y, Milner JJ, Pritykin Y, Pucci F, Scharping NE, Sudmeier L, Wang Y, Wieland A, Williams MM. Lessons for the next generation of scientists from the 2nd annual Arthur and Sandra Irving Cancer Immunology Symposium. Cancer Immunology Research. Cancer Immunol Res. 2023 Oct 31:OF1-OF7.

2022

Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022 Apr 13;14(640):eabn2231.

2021

Evgin L, Vile RG. Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals? Cancers (Basel). 2021 Mar 5;13(5):1106. 

2020

Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, Archer G, Sampson J, Pulido J, Perez LS, Vile R. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat Commun. 2020 Jun 24;11(1):3187